Search and analyze individual stocks with comprehensive metrics
AstraZeneca Pharma India Ltd
Fundamental Score
AstraZeneca Pharma India Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of ASTRAZEN across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (23.63%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (33.40%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Robust Profit Growth (51.26%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (37.03%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Consistent Growth Track Record (15.59% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Excellent EPS Growth (19.45% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (19.45% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Conservative Debt Levels (D/E: 0.04)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (131.37x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹329.01 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (75.00%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 97.79x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Limited Institutional Interest (FII+DII: 8.00%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for AstraZeneca Pharma India Ltd
About ASTRAZEN
Business Overview
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
Company Details
Key Leadership
Corporate Events
ASTRAZEN Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of AstraZeneca Pharma India Ltd (ASTRAZEN)?
As of 19 Jan 2026, 10:11 am IST, AstraZeneca Pharma India Ltd (ASTRAZEN) is currently trading at ₹8298.00. The stock has a market capitalization of ₹22.61K (Cr).
Is ASTRAZEN share price Overvalued or Undervalued?
ASTRAZEN is currently trading at a P/E ratio of 97.79x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the AstraZeneca Pharma India Ltd share price?
Key factors influencing ASTRAZEN's price include its quarterly earnings growth (Sales Growth: 37.03%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is AstraZeneca Pharma India Ltd a good stock for long-term investment?
AstraZeneca Pharma India Ltd shows a 5-year Profit Growth of 19.45% and an ROE of 23.63%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.04 before investing.
How does AstraZeneca Pharma India Ltd compare with its industry peers?
AstraZeneca Pharma India Ltd competes with major peers in the Pharmaceuticals. Investors should compare ASTRAZEN's P/E of 97.79x and ROE of 23.63% against the industry averages to determine its competitive standing.
What is the P/E ratio of ASTRAZEN and what does it mean?
ASTRAZEN has a P/E ratio of 97.79x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹98 for every ₹1 of annual earnings.
How is ASTRAZEN performing according to Bull Run's analysis?
ASTRAZEN has a Bull Run fundamental score of 65.5/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does ASTRAZEN belong to?
ASTRAZEN operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting AstraZeneca Pharma India Ltd.
What is Return on Equity (ROE) and why is it important for ASTRAZEN?
ASTRAZEN has an ROE of 23.63%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently AstraZeneca Pharma India Ltd generates profits from shareholders' equity.
How is ASTRAZEN's debt-to-equity ratio and what does it indicate?
ASTRAZEN has a debt-to-equity ratio of 0.04, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is ASTRAZEN's dividend yield and is it a good dividend stock?
ASTRAZEN offers a dividend yield of 0.35%, which means you receive ₹0.35 annual dividend for every ₹100 invested.
How has ASTRAZEN grown over the past 5 years?
ASTRAZEN has achieved 5-year growth rates of: Sales Growth 15.59%, Profit Growth 19.45%, and EPS Growth 19.45%.
What is the promoter holding in ASTRAZEN and why does it matter?
Promoters hold 75.00% of ASTRAZEN shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is ASTRAZEN's market capitalization category?
ASTRAZEN has a market capitalization of ₹22605 crores, placing it in the Large-cap category.
How volatile is ASTRAZEN stock?
ASTRAZEN has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for ASTRAZEN?
ASTRAZEN has a 52-week high of ₹N/A and low of ₹N/A.
What is ASTRAZEN's operating profit margin trend?
ASTRAZEN has a 5-year average Operating Profit Margin (OPM) of 14.65%, indicating the company's operational efficiency.
How is ASTRAZEN's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 37.03% and YoY Profit Growth of 51.26%.
What is the institutional holding pattern in ASTRAZEN?
ASTRAZEN has FII holding of 2.74% and DII holding of 5.26%. Significant institutional holding often suggests professional confidence in the stock.